Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Berlex’ Yaz Gains Indication For Premenstrual Dysphoric Disorder

This article was originally published in The Pink Sheet Daily

Executive Summary

The oral contraceptive is the first approved for the treatment of emotional and physical symptoms of PMDD.

You may also be interested in...



Bayer Puts Marketing Muscle Behind Yaz

Company is exclusively promoting the oral contraceptive Yaz in the U.S. as it looks to drive uptake over Yasmin.

Bayer Puts Marketing Muscle Behind Yaz

Company is exclusively promoting the oral contraceptive Yaz in the U.S. as it looks to drive uptake over Yasmin.

Bayer, Intendis To Copromote Yaz For Acne/Birth Control Indication

Bayer leverages Intendis sales force to promote new dermatology indication for oral contraceptive, firm tells “The Pink Sheet” DAILY.

Related Content

Topics

UsernamePublicRestriction

Register

PS063315

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel